- Home
- CPD Activities
- Early assessment of antiretroviral efficacy is critical to prevent the emergence of resistance mutations in HIV-tuberculosis coinfected patients: a substudy of the CARINEMO-ANRS12146 trial
Early assessment of antiretroviral efficacy is critical to prevent the emergence of resistance mutations in HIV-tuberculosis coinfected patients: a substudy of the CARINEMO-ANRS12146 trial
| Name | World Continuing Education Alliance |
|---|
| Activity Title | Early assessment of antiretroviral efficacy is critical to prevent the emergence of resistance mutations in HIV-tuberculosis coinfected patients: a substudy of the CARINEMO-ANRS12146 trial |
|---|
| Details | Antiretroviral therapy (ART) aims to sustain virological suppression, which is associated with a clinical benefit and immune recovery. It also prevents HIV transmission and limits the emergence of antiretroviral (ARV) drug resistance. In a recent meta-analysis, Gupta. In 2016, 80% of the worldwide prescription of ART-included efavirenz (EFV), a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-class drug. The phase 3 CARINEMO randomized clinical trial enrolled 570 HIV-TB coinfected patients in Mozambique, Africa, and compared the efficacy and safety of two NNRTIs (nevirapine [NVP] and EFV) for ART-naïve patientsn |
|---|
| Competence | Public Health |
|---|
| Start Date | <span class="not-set">(not set)</span> |
|---|
| End Date | <span class="not-set">(not set)</span> |
|---|
| Event Time | 11:30 AM |
|---|
| Location | World Continuing Education Alliance eLearning System |
|---|
| Cost (UGX) | 0 |
|---|
| CPD Points | 1 |
|---|